Univo IRB, a next generation institutional review board (IRB) backed by QHP Capital, today announced Julie Blasingim has been promoted to CEO by Univo’s board of directors. As CEO, Blasingim will drive Univo IRB’s strategic growth and innovation, bringing a modern iteration of IRB solutions to unify patients and research, and support today’s clinical trials.

Blasingim, formerly President, has over 20 years of experience in the clinical research industry. She started her career on the research site compliance side before serving in several leadership roles across multiple central IRBs including Independent IRB, Schulman, and Advarra. Her blend of research site and review board experience gives her a unifying perspective that benefits all parties in conducting good and safe clinical trials.

“I am humbled at this opportunity to serve our research patients and community in a better way and look forward to leading our talented team to drive not only the growth of Univo IRB, but also the future of modern IRBs for the industry,” Blasingim said. “We understand what it takes to execute high-quality, compliant, and safe clinical trials and are committed to unifying clinical research with our passion for patient protection, education, and advocacy as a trusted partner for IRB review.”

“Building on the momentum of Univo IRB’s recently announced new company name and plans to bring the voice of patients closer to research, Julie’s appointment as CEO continues the exciting new chapter for the organization,” said Michael Sorensen, Lead Investment Partner for Univo IRB at majority owner QHP Capital. “The IRB sector has seen significant changes, bringing challenges and delays. Industry feedback has been overwhelmingly positive for another IRB option. With Julie’s leadership coming together along with her seasoned executive team including, Cyrus Gill, Executive IRB Chair, and Heather Fitzgerald, VP of Operations, Univo IRB is poised to continue making an impact on the research community. This is just the beginning of more exciting announcements to come.”

About Univo IRB

Univo IRB, formerly Principal IRB, is a next generation institutional review board (IRB) specializing in the ethical review of Phase I-IV pharmaceutical, device, biologic, behavioral, and psycho-social research. We offer agile study approaches, expert solutions powered by industry-leading study technology, and a service-first approach. Univo IRB holds accreditation through the Association for the Accreditation of Human Research Protection Programs (AAHRPP). With support from senior advisors and 60+ years of industry experience, Univo IRB guides your study to approval while respecting the rights and welfare of patients every step of the way.

About QHP Capital

QHP Capital, L.P. invests in lower middle market healthcare companies primarily in North America, with a focus on services and technology companies where a strategic partner and operating resources can accelerate growth. Targeting companies in healthcare and pharmaceutical services industries, QHP invests in the form of buyouts, growth equity, and recapitalizations.